Research programme: skeletal muscle activators - Cytokinetics/Astellas

Drug Profile

Research programme: skeletal muscle activators - Cytokinetics/Astellas

Alternative Names: CK 3672889; CK-1909178; CK-2066260

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokinetics
  • Developer Astellas Pharma; Cytokinetics
  • Class Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Muscular atrophy

Most Recent Events

  • 03 Jan 2018 Cytokinetics extends the joint research programme with Astellas Pharma through 2019
  • 27 Jul 2016 Cytokinetics and Astellas Pharma expand their collaboration for discovery of skeletal muscle activators through 2017 and also include Amyotrophic lateral sclerosis in target indications
  • 30 Jul 2015 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top